ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1752

Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint

Chunyan Xiang1, Soomin Hong1, Bingjiao Zhao2, Hui Pi3, Fang Du4, Xingyu Lu5, Yuanjia Tang1, Nan Shen6, Chunxi Yang7 and Runci Wang8, 1Shanghai Institute of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 2Department of Orthodontics, Shanghai Stomatological Hospital & School of Stomatology, Fudan University, Shanghai, China, 3Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China, 4Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 5Department of Endocrinology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 6Shanghai Jiao Tong University School of Medicine, Shanghai, China, 7Department of Orthopedics, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (SJTUSM), Shanghai, China, 8Renji hospital, Shanghai Jiaotong University, Pudong Xinqu, China

Meeting: ACR Convergence 2023

Keywords: Fibroblasts, Synovial, immunology, Micro-RNA, Osteoarthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Peripheral neuroimmune crosstalk plays a crucial role in the inflammatory process and bone metabolism in joint. Serotonin receptor HTR2A was reported to be expressed on immune cells, of which gene polymorphisms are associated with an increased risk of developing RA and other autoimmune disease. However, the expression and regulation of HTR2A in arthritis synovium remain poorly understood.

Methods: Differential expression of neurotransmitter receptors (NTRs) and their correlated inflammatory molecules was identified in RA and OA synovium from public scRNA-seq dataset[1]. IHC staining of synovial tissue from RA and OA patients was performed for validation. Expression of miRNAs potentially targeting HTR2A carried by synovial fluid extracellular vesicles (EVs) was screened in low- and high-grade inflammation RA from public dataset[2] and validated by qPCR.

Results: HTR2A was expressed by 34.3% and 42.1% of fibroblasts in OA and RA synovium, while barely expressed by synovial leukocytes. Higher level of IL-6, IFN-????, IFN stimulated genes, chemokines including CCL2, CCL8, CCL13, CXCL9, and CXCL12, and MMPs and VEGFB were observed on all cell types in RA joint, indicating a highly inflammatory microenvironment in RA. (Fig.1).

Correlation analysis showed positive correlation of HTR2A with IL6, CCL5, CXCL12, TNFSF11 and VEGFC expression in fibroblast specifically as well as in all synovial cells. The strongest correlation was found between HTR2A and CXCL12 (R=0.45). Transcriptomic findings above were confirmed on the protein level with IHC staining of RA and OA synovial tissue from patients. There was significantly upregulated expression of HTR2A on RA whole synovial tissue level and fibroblast level. Increased expression of IL-6 and CXCL12 was also found in RA synovial tissue (Fig.2).

To investigate what could regulate the different HTR2A expression in RA and OA, we examined the content of EVs derived from RA and OA synovial fluid. Integrated with public RNAseq data, TargetScan and RNAhybrid prediction, 6 miRNAs predicted to regulate HTR2A expression, miRNA-23b-3p, miR-23b-5p, miR-214-3p, miR-3120-5P, miR-615-3p, and miR-4508, were significantly lower in RA EVs. A trend of lower expression of these 6 miRNAs was demonstrated by qPCR (Fig.3).

Conclusion: A neurotransmitter receptor of serotonin, HTR2A, was enriched in rheumatoid arthritis (RA) synovial fibroblast and positively correlated with inflammation. 6 miRNAs targeting HTR2A were decreased in RA synovial fluid EVs comparing to osteoarthritis. HTR2A may contribute to inflammation and RA pathogenesis, and miRNAs targeting HTR2A might offer new therapeutic strategies to alleviate inflammation in RA.

Supporting image 1

Figure 1. HTR2A and effectors expression pattern in joint synovial tissue of RA and OA patients. (a) Expression level and (b) positive percentage of HTR2A in RA and OA synovial fibroblast, (c) expression level and (d) positive percentage of inflammatory molecules in RA and OA synovium. Statistical test by Mann–Whitney U test in (a) and (c), *p < 0.05, **p < 0.01, ***p < 0.001,****p < 0.0001. Statistical test by Chi-square or Fisher's exact test in (b) and (d), *p < 0.05.

Supporting image 2

Figure 2. Inflammatory correlation and miRNA regulation of HTR2A in arthritis joints. (a) Heatmap showing correlation between HTR2A and inflammatory molecules using Pearson correlation. (b) Significant correlation plot between HTR2A and representative inflammatory molecules in fibroblast or all synovial cells. (c) 40x field view and quantification of immunohistochemical staining of HTR2A, IL6 and CXCL12 in synovial tissue of RA (n=5) and OA (n=4) patients, p values were calculated by Mann–Whitney U test, *p < 0.05, **p < 0.01, ***p < 0.001,****p < 0.0001.

Supporting image 3

Figure 3. miRNAs targeting HTR2A carried by synovial fluid EVs. (a) Venn diagram of miRNAs targeting HTR2A. miRNAs predicted by TargetScan (orange) and RNAhybrid (green) databases, and miRNAs lowly expressed in high-inflammation RA synovial fluid EVs (blue). (b) miRNAs were extracted from OA(n=7) and RA(n=4) synovial fluid EVs, and the expression of 6 miRNAs targeting for HTR2A were validated by qPCR. p values were calculated by t-test. *p < 0.05, **p < 0.01, ***p < 0.001.


Disclosures: C. Xiang: None; S. Hong: None; B. Zhao: None; H. Pi: None; F. Du: None; X. Lu: None; Y. Tang: None; N. Shen: None; C. Yang: None; R. Wang: None.

To cite this abstract in AMA style:

Xiang C, Hong S, Zhao B, Pi H, Du F, Lu X, Tang Y, Shen N, Yang C, Wang R. Fibroblast Expression of Neurotransmitter Receptor HTR2A Associates with Inflammation in Rheumatoid Arthritis Joint [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/fibroblast-expression-of-neurotransmitter-receptor-htr2a-associates-with-inflammation-in-rheumatoid-arthritis-joint/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fibroblast-expression-of-neurotransmitter-receptor-htr2a-associates-with-inflammation-in-rheumatoid-arthritis-joint/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology